UBS Group AG Lowers Position in Praxis Precision Medicines, Inc. $PRAX

UBS Group AG cut its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) by 7.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 89,200 shares of the company’s stock after selling 7,612 shares during the quarter. UBS Group AG’s holdings in Praxis Precision Medicines were worth $26,291,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of PRAX. NBC Securities Inc. purchased a new stake in shares of Praxis Precision Medicines in the fourth quarter worth approximately $38,000. GAMMA Investing LLC grew its holdings in shares of Praxis Precision Medicines by 58.7% in the fourth quarter. GAMMA Investing LLC now owns 238 shares of the company’s stock valued at $70,000 after acquiring an additional 88 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Praxis Precision Medicines by 24.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company’s stock valued at $77,000 after purchasing an additional 359 shares during the period. AlphaQuest LLC boosted its holdings in shares of Praxis Precision Medicines by 1,623.3% in the third quarter. AlphaQuest LLC now owns 1,999 shares of the company’s stock worth $106,000 after acquiring an additional 1,883 shares during the period. Finally, Farther Finance Advisors LLC raised its position in shares of Praxis Precision Medicines by 60.0% in the fourth quarter. Farther Finance Advisors LLC now owns 368 shares of the company’s stock worth $108,000 after buying an additional 138 shares in the last quarter. 67.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PRAX. Wolfe Research initiated coverage on Praxis Precision Medicines in a research report on Monday, February 23rd. They issued an “outperform” rating and a $500.00 price objective on the stock. BTIG Research restated a “buy” rating and set a $843.00 price target on shares of Praxis Precision Medicines in a research report on Friday. Raymond James Financial began coverage on Praxis Precision Medicines in a report on Friday, April 10th. They issued a “strong-buy” rating and a $815.00 price objective on the stock. TD Cowen reissued a “buy” rating on shares of Praxis Precision Medicines in a research note on Thursday, January 29th. Finally, Robert W. Baird set a $433.00 price objective on Praxis Precision Medicines and gave the company an “outperform” rating in a research report on Friday, February 20th. Five research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $591.83.

Praxis Precision Medicines Price Performance

Shares of PRAX opened at $330.02 on Monday. The business’s 50 day moving average price is $317.78 and its 200-day moving average price is $277.56. Praxis Precision Medicines, Inc. has a 52 week low of $35.21 and a 52 week high of $356.00. The stock has a market cap of $9.20 billion, a P/E ratio of -24.68 and a beta of 2.76.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($3.20) EPS for the quarter, topping analysts’ consensus estimates of ($3.58) by $0.38. On average, equities analysts anticipate that Praxis Precision Medicines, Inc. will post -15.16 EPS for the current year.

More Praxis Precision Medicines News

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: The company reported first-quarter 2026 results with a smaller-than-expected loss, as EPS of ($3.20) beat estimates of ($3.58), which can help reassure investors ahead of future commercialization. Praxis earnings report
• Positive Sentiment: Praxis said the FDA accepted NDA filings for ulixacaltamide in essential tremor and relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies, giving the pipeline clearer regulatory timelines and potential catalysts in 2026-2027. Corporate update and Q1 2026 results
• Neutral Sentiment: BTIG reiterated a Buy rating and raised its price target sharply to $843, signaling strong long-term optimism even after the stock’s recent run-up. BTIG research update
• Negative Sentiment: Wedbush raised its target to $166 but kept an Underperform rating, highlighting meaningful downside risk versus the current share price and creating a conflicting message for investors. Wedbush rating update
• Neutral Sentiment: A Globe and Mail article noted analysts are bullish on Praxis alongside other healthcare names, adding to the broader positive attention on the stock. Analysts bullish on PRAX

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.